Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1707 | Interview by psychologists Wiki | 1.00 |
drug2490 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D006948 | Hyperkinesis NIH | 1.00 |
D002659 | Child Development Disorders, Pervasive NIH | 0.71 |
D001289 | Attention Deficit Disorder with Hyperactivity NIH | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002487 | Hyperkinetic movements HPO | 1.00 |
HP:0000717 | Autism HPO | 0.71 |
HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000729 | Autistic behavior HPO | 0.58 |
Navigate: Correlations HPO
There is one clinical trial.
The study aim to test proof of concept of CBD treatment for efficacy and safety in patients suffering with mild COVID-19 infection. The CBD will be delivered via oil droplets not containing THC, compared to placebo.
Description: Patients chance of clinical deterioration of COVID19 disease as defined by percentage of patients requiring oxygen therapy during their hospitalization.
Measure: Clinical deterioration Time: 14 daysDescription: NEWS2- National Early Warning Score - a score defining the probability of severe COVID 19 disease. Minimum score is 0, while maximum score is 23. Higher score means worse outcome
Measure: Changes in NEWS scale Time: 14 daysDescription: Percentage of patients requiring the respiratory support of either of the following : high flow nasal canula oxygen support, mechanical ventilation or use of extra corporeal membrane oxygenation.
Measure: Supportive care therapies Time: 14 daysDescription: Presence of SARS-COV2 in oral & nasal secretions in days 10, 14 of the study
Measure: SARS-COV2 presence Time: 10 days, 14 daysDescription: Hospitalization days due to COVID-19
Measure: Hospitalization Days Time: 14 daysDescription: IL2, IL18, IL8. IL6, IL10, TNF-alpha, TGF-beta levels at day 3, day 7 and discharge day (which is on average the 10th day of hospitalization). All cytokine levels would be measured by pg/mL.
Measure: Cytokine Levels Time: Day 3, day 7, discharge day (which is on average the 10th day of hospitalization).Description: A verified score measuring anxiety. Minimum score is 0, while maximum score is 56. Higher scores mean worse outcome.
Measure: Hamilton Anxiety Score Time: 14 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports